Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.77% | -30.77% | -39.08% | -76.22% | -74.49% |
| Total Depreciation and Amortization | 1.57% | 4.11% | 12.75% | 31.72% | 56.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.66% | 28.76% | 19.43% | 17.65% | 5.90% |
| Change in Net Operating Assets | 83.08% | 117.09% | 163.69% | 169.46% | -1,407.72% |
| Cash from Operations | 5.68% | -3.64% | -19.74% | -82.82% | -136.51% |
| Capital Expenditure | 37.45% | 76.01% | 88.71% | 90.31% | 94.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,605.33% | -3,652.11% | -32.81% | 87.02% | 110.52% |
| Cash from Investing | -3,954.19% | -2,766.69% | -28.95% | 87.20% | 108.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.47% | -5.05% | 5.20% | -282.96% | -2,694.74% |
| Issuance of Common Stock | 57.00% | 272.54% | 63.45% | -47.73% | 48.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -82.98% | -82.98% | -82.98% | -- | -- |
| Cash from Financing | 55.69% | 295.23% | 62.72% | -52.59% | 40.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -178.80% | 1,619.57% | 2,204.69% | -92.46% | 1,656.85% |